Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc (SBFM) combines generic drug commercialization with cutting-edge research in oncology and antiviral therapies. This news hub provides investors and healthcare stakeholders with essential updates about the company's operational developments and scientific advancements.
Access timely press releases covering regulatory milestones, financial results, and research breakthroughs. Our curated collection includes updates on SBFM's generic drug portfolio through subsidiary Nora Pharma, plus progress reports on proprietary initiatives like the K1.1 mRNA-LNP cancer treatment and PLpro protease inhibitor program.
Key content categories include quarterly earnings announcements, partnership disclosures, clinical trial updates, and market expansion news. All materials are sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to SBFM's latest developments. Regularly updated content helps stakeholders monitor both the company's established generics business and its innovative drug development pipeline in critical therapeutic areas.
Sunshine Biopharma (SBFM) has secured $2,054,000 in financing, exceeding the initially announced $2,000,000 from RB Capital Partners. This funding, convertible at $0.43 per share, will support the development of its Coronavirus treatment and the anticancer drug Adva-27a, targeting pancreatic cancer. The company is conducting studies in collaboration with the University of Georgia to assess the efficacy of its antiviral compounds in transgenic mice. Clinical trials for Adva-27a are planned at McGill University’s Jewish General Hospital.
Sunshine Biopharma (SBFM) announced a 'Notice of Allowance' from the European Patent Office for a new patent on its anticancer compound, Adva-27a, extending its European protection until 2033. This follows a similar patent granted in the U.S. in 2019. Sunshine Biopharma is the sole owner of Adva-27a's intellectual property. The compound shows promising results against multidrug-resistant cancers, with upcoming clinical trials planned at McGill University. The company is also developing antiviral treatments for COVID-19, aiming to advance multiple compounds for clinical testing.
Sunshine Biopharma (SBFM) has announced the shipment of a new batch of Adva-27a from China to its laboratories in Montreal. Following quality assurance testing, the company will conduct tumor inhibition studies on xenograft mice with human pancreatic cancer. Adva-27a has shown promise in preclinical trials against various cancer types, including pancreatic cancer, known for its resistance to chemotherapy. Clinical trials are planned at McGill University’s Jewish General Hospital. The company also continues development on COVID-19 treatments.
Sunshine Biopharma (OTC PINK: SBFM) announced the launch of its new eCommerce website, Nutrition.SunshineBiopharma.com, featuring over 20 nutritional products, including amino acids and vitamins. The site supports customers in browsing and ordering supplements conveniently. Essential 9™, one of the featured products, contains all nine essential amino acids crucial for protein synthesis and immune support. With eCommerce sales projected to grow from $374 billion in 2020 to $476 billion by 2024, Sunshine aims to enhance its market presence while maintaining strict manufacturing standards.
Sunshine Biopharma (SBFM) has launched its new eCommerce website, Nutrition.SunshineBiopharma.com, featuring over 20 nutritional products, including Essential 9™, designed to support optimal health. The website aims to enhance the shopping experience for consumers seeking high-quality nutritional supplements, available 24/7. With eCommerce sales projected to rise from $374 billion in 2020 to $476 billion by 2024, the launch positions SBFM to capitalize on the growing market.
Sunshine Biopharma (OTC PINK:SBFM) announced the start of a critical transgenic mice study for its COVID-19 treatment, aimed at inhibiting virus replication via protease inhibitors. The study, conducted at the University of Georgia, uses genetically modified mice susceptible to SARS-CoV-2. Success in these studies may lead to FDA submissions for human trials. Sunshine Biopharma's COVID-19 treatment has seen progress since its provisional patent filing in May 2020, with a lead compound identified as SBFM-PL4.
Sunshine Biopharma (OTC PINK:SBFM) announced an exclusive license agreement with the University of Georgia for two patented Anti-Coronavirus compounds. This partnership aims to advance the compounds' development alongside SBFM-PL4, Sunshine's lead Anti-Coronavirus compound. The efficacy testing will involve genetically modified mice susceptible to SARS-CoV-2, with trials expected to commence this month. Furthermore, Sunshine is actively developing Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells and planning clinical trials for pancreatic cancer.
Sunshine Biopharma (OTC PINK:SBFM) has successfully paid off over $100,000 in convertible notes, aiming to reduce dilution and enhance shareholder value. The CFO, Camille Sebaaly, expressed commitment to operational growth and prioritizing shareholders' interests. The company continues its development on SBFM-PL4, a COVID-19 treatment in collaboration with the University of Georgia, and Adva-27a, an anticancer compound effective against multidrug-resistant cancers. Clinical trials for Adva-27a are planned at McGill University.
Sunshine Biopharma Inc. (OTC PINK:SBFM) announced receiving the third tranche of $800,000 from a $2,000,000 financing agreement with RB Capital Partners Inc. This funding supports the priority development of their Coronavirus treatment and clinical advancement of Adva-27a, an anticancer drug targeting pancreatic cancer. The company aims to combat SARS-CoV-2 through new molecules that inhibit viral replication. Ongoing testing and collaboration with the University of Georgia are key aspects of their development strategy.
Sunshine Biopharma (OTC PINK:SBFM) is advancing its Anti-Coronavirus drug development amidst the ongoing pandemic. Recognizing the necessity for effective treatments alongside vaccines, the company emphasizes the importance of an oral treatment option. Sunshine Biopharma has filed a provisional patent for novel compounds inhibiting Coronavirus proteases, with lead candidate SBFM-PL4 currently in in vitro testing. Additionally, the company is developing Adva-27a, an anticancer drug showing efficacy against multidrug-resistant cancers, with clinical trials planned at McGill University.
FAQ
What is the current stock price of Sunshine Biopharma (SBFM)?
What is the market cap of Sunshine Biopharma (SBFM)?
